Capricor Therapeutics, Inc. (FRA:4LN2)
Germany · Delayed Price · Currency is EUR | Market Cap | 356.12M +29.5% |
| Revenue (ttm) | n/a |
| Net Income | -99.39M |
| EPS | -2.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 6.03 |
| Previous Close | 6.15 |
| Day's Range | 5.97 - 6.03 |
| 52-Week Range | 3.73 - 30.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]
News
Capricor Therapeutics downgraded to Neutral from Buy at Alliance Global
Alliance Global downgraded Capricor Therapeutics (CAPR) to Neutral from Buy with a price target of $7, down from $51. The upcoming deramiocel FDA panel looks like an uphill battle based…
Capricor Therapeutics downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded Capricor Therapeutics (CAPR) to Neutral from Buy with a price target of $7, down from $38, after the FDA issued its briefing documents ahead of the advisory…
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and direc...
B. Riley downgrades Capricor as FDA briefing docs ‘incompatible with approval’
As previously reported, B. Riley analyst Madison El-Saadi downgraded Capricor Therapeutics (CAPR) to Neutral from Buy with a price target of $10, down from $63, following the release of the…
Capricor says analyses in FDA’s briefing materials ‘rely on’ SAP version 1.1
Capricor Therapeutics (CAPR) provided an update ahead of the Company’s upcoming FDA Advisory Committee meeting, at which an independent advisory committee will discuss Capricor’s Biologics License App...
Capricor Therapeutics downgraded to Neutral from Buy at B. Riley
B. Riley downgraded Capricor Therapeutics (CAPR) to Neutral from Buy with a price target of $10, down from $63.
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provid...
Capricor Therapeutics plunges after FDA posts deramiocel briefing notes
Shares of Capricor Therapeutics (CAPR) have fallen $12.47, or 63% to $7.23 in early Monday trading after the FDA posted briefing documents for the the Cellular, Tissue, and Gene Therapies…
Oppenheimer would own Capricor Therapeutics into committee meeting
After briefing documents for this Wednesday’s FDA advisory committee for deramiocel became available this morning, Oppenheimer analyst Leland Gershell admits “surprise” around certain differences betw...
FDA staff flags concerns for Capricor's Duchenne heart disease therapy
U.S. Food and Drug Administration staff reviewers raised concerns about whether Capricor Therapeutics' cell therapy deramiocel has sufficient evidence of effectiveness for treating cardiomyop...
Capricor announces FDA advisory committee meeting to review Deramiocel BLA
Capricor Therapeutics (CAPR) announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration is planning to convene an advisory committee meeting to...
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026–
Capricor presents five-year data from HOPE-2 open-label extension study
Capricor Therapeutics (CAPR) announced five-year data from its ongoing HOPE-2 open-label extension study of Deramiocel, the company’s lead cell therapy candidate for Duchenne Muscular Dystrophy, or DM...
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ...
Caprock Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that it has closed its previously announced non-brokered priva...
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.
Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Frank Guillemette (the "Acquiror") announces that, on June 12, 2026, he acquired an aggregate of 200,000 common shares in the capital of Caprock Mi...
Capricor Therapeutics management to meet with Oppenheimer
Meeting to be held on June 22-23 hosted by Oppenheimer.
Caprock Announces Proposed Private Placement
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce a proposed non-brokered private placement offering of up to 6,...
Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes from...
Capricor Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
HOPE-3 trial data supports regulatory progress for deramiocel in Duchenne muscular dystrophy, with a PDUFA date in August 2026. Commercial launch preparations are underway, including manufacturing scale-up and payer engagement, while legal action with NS Pharma proceeds independently.
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ...
Capricor Therapeutics Slides: Corporate presentation
Capricor Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Capricor Therapeutics (CAPR) to $38 from $43 and keeps a Buy rating on the shares. Roth notes that while…
Capricor Therapeutics Earnings Call Transcript: Q1 2026
FDA review of deramiocel is progressing with a PDUFA date set for August 2026, while legal action seeks to enable independent commercialization due to a flawed distribution agreement. Financials show strong liquidity and increased investment in launch readiness, with manufacturing and commercial teams being rapidly scaled.
Capricor Therapeutics Earnings release: Q1 2026
Capricor Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.